• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Revenue Slump Might Change The Case For Investing In IDEAYA Biosciences (IDYA)

    Simply Wall St·11/12/2026 04:54:01
    Listen to the news
    • IDEAYA Biosciences reported third quarter 2026 revenue of US$10.24 million and a net loss of US$125.75 million, compared with revenue of US$207.83 million and net income of US$119.24 million in the same period a year earlier. The company also filed a US$94.92 million shelf registration for 3,000,000 common shares related to its ESOP.
    • The sharp swing from profit to loss, alongside much lower revenue and a new shelf registration, highlights higher cost and funding pressures as IDEAYA Biosciences advances its precision oncology programs toward later stage development and potential commercialization.
    • Attention now turns to how IDEAYA Biosciences' weaker recent earnings, especially the larger net loss, may influence the broader investment narrative.

    Pressure test IDEAYA Biosciences against other high research spend stories by scanning 19 high quality undiscovered gems that could be moving under most investors' radar.

    IDEAYA Biosciences Investment Narrative Recap

    To stay invested in IDEAYA Biosciences, you need to be comfortable with a high research spend story where the main prize is potential approval and use of assets like darovasertib and IDE849. The latest quarter, with revenue of US$10.24 million and a net loss of US$125.75 million, reinforces that this is still a funding heavy development phase.

    The analyst consensus Narrative on Simply Wall St leans on future darovasertib and pipeline contributions. The enlarged losses primarily sharpen the focus on cash use and execution risk. In the near term, the most important catalyst remains regulatory progress on darovasertib, while the biggest risk is any delay or limitation on that NDA review and label scope.

    The US$94.92 million shelf registration tied to 3,000,000 common shares for the ESOP sits squarely in this context. It signals planning for additional equity issuance capacity at a time when IDEAYA Biosciences is reporting a much larger net loss for both the quarter and the nine month period.

    For you as a shareholder or potential investor, this filing matters because the analyst consensus Narrative on Simply Wall St already assumes share count growth and continued losses over the next three years. Any use of this shelf would add to dilution risk. This sits alongside clinical and regulatory milestones as a key factor when weighing the darovasertib and broader pipeline catalysts.

    IDEAYA Biosciences' current analyst story points to revenues of $435.3 million and earnings of $75.0 million by 2029. This lines up with the assumption of 23.0% yearly revenue growth and an earnings move of about $250.0 million from earnings today of $175.0 million in losses to the $75.0 million consensus forecast.

    Uncover why IDEAYA Biosciences' fair value indicates a 61% potential upside to its current price, which could narrow quickly.

    NasdaqGS:IDYA 1-Year Stock Price Chart
    NasdaqGS:IDYA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on IDEAYA Biosciences places greater emphasis on the potential of darovasertib to reshape future earnings. The most optimistic analysts were estimating about US$583.0 million of revenue and US$100.5 million of earnings by 2029, before this earnings release. You can treat today’s much weaker results as a prompt to compare those optimistic projections with more cautious opinions.

    Explore 2 other IDEAYA Biosciences fair value estimates, including one that suggests as much as 61% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond IDEAYA Biosciences?

    If the IDEAYA Biosciences story has you thinking about position sizing, risk tolerance, and where to find your next candidate, broaden your watchlist using the Simply Wall St screener to compare very different types of opportunities side by side.